Predictive Genomics for Prevention, Interception and Cure Health Datapalooza

Similar documents
PAREXEL GENOMIC MEDICINE SERVICES. Applying genomics to enhance your drug development journey

Update on Real World Evidence Data Collection

Personalized. Health in Canada

WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES.

Efficient Use of EHR Data for Translational Research

THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION

TRANSFORMING GLOBAL GENETIC DATA INTO MEDICAL DECISIONS

The Five Key Elements of a Successful Metabolomics Study

Rare Diseases: Challenges and Opportunities NIH Perspective

Translational Research

The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence

Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013

New Frontiers in Personalized Medicine

Use of Big Data to Support Regulatory Decision Making

Roundtable on Genomics and Precision Health Annual Report

Optimising Clinical Laboratory Operations. Alan Brown SLAS Compound Management March 2017

ict Multi-Year Grants Funding Opportunity

Population Genetics & Drug Discovery

Future Challenges in Fujitsu s Healthcare Business Activities of Next-Generation Healthcare Innovation Center

Molecular Diagnostics

ICH Topic E15 Definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories.

Type of Activity. Universal Activity Number L04-P

NHS ENGLAND BOARD PAPER

The importance of regulatory science in a societal and industrial perspective Annual Conference CORS 24 November 2016

Genomics And Pharmacogenomics In Anticancer Drug Development And Clinical Response (Cancer Drug Discovery And Development)

Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare

Optimization: The Next Frontier

Research Strategy Delivering internationally excellent research for a healthy, safe and sustainable society

The Future of HealthCare Information Technology

The Future of Clinical and Pharmaceutical Research

TOTAL CANCER CARE: CREATING PARTNERSHIPS TO ADDRESS PATIENT NEEDS

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development

Life Sciences Practice

Building molecular handprints: a systems biology approach to complex diseases

Reimbursement Strategy for Companion Diagnostics:

Personalized Medicine

How Australia can lead the way to precision medicine. Isaac S. Kohane, MD, PhD

Utilizing Innovative Statistical Methods. Discussion Guide

Department At-A-Glance

Genomic Medicine in France

Terminology for personalized medicine

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3

Enabling faster insights to improve clinical trial efficiency and quality

Perspective: Convergence of CLIA and FDA Requirements A Rational Shift in the Regulatory Paradigm

Developing Data Models and Standards to Support Use Cases

Roche in Australia Innovation Leader

Dana-Farber Cancer Institute Speeds Medical Research with Advanced Data Warehouse

e-pkgene: A knowledge-based research tool for analysing the impact of genetics on drug exposure

Enabling Precision Medicine: The Role of Genetics in Clinical Drug Development A Workshop

Big Data Era in Medicine

REIMAGINING DRUG DEVELOPMENT:

Introducing a Highly Integrated Approach to Translational Research: Biomarker Data Management, Data Integration, and Collaboration

Strategic Plan. Uniting to care & cure

"Stratification biomarkers in personalised medicine"

Proposal of Recommendations for a Personalised Precision Medicine National Strategy. Anticipating the future. Accelerating changes.

The In Vitro Diagnostic CRO

OB/GYN EHR Specialty Content

Making the entire pharmaceutical chain sustainable. Bengt Mattson. Policy Manager, LIF (Manager,CSR & Environmental Affairs, Pfizer AB)

Summary of Provisions in 21 st Century Cures Act (H.R. 6) as passed by full House of Representatives, July 10, 2015

State of the Art in Data Management for Precision Medicine & Genomics. March 8, pm 3 pm ET

Overview of the Luxembourg biomedical and health research ecosystem FNR FRANK GLOD LUXCOR HEALTH EVENT MONDAY 19 JUNE 2017

Nanotechnology and Advanced Materials for more effective Healthcare

Data Sources and Biobanks in the Asia-Pacific Region. Wei Zhou, MD, Ph.D. Department of Epidemiology, Merck Research Laboratories October 23, 2014

DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE

Analyzing Big Data: The Path to Competitive Advantage

RWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.

Bridging the Genomics-Health IT Gap for Precision Medicine

European Induced Pluripotent Stem Cell Bank

Clinical Research Service Provider Information Form

Building on the NHLBI Legacy of Hypertension Research:

Human Genomics, Precision Medicine, and Advancing Human Health. The Human Genome. The Origin of Genomics : 1987

E2ES to Accelerate Next-Generation Genome Analysis in Clinical Research

Genomics Market Share, Size, Analysis, Growth, Trends and Forecasts to 2024 Hexa Research

TECHNOLOGIES, PRODUCTS & SERVICES for MOLECULAR DIAGNOSTICS, MDx ABA 298

PREDICTIVE ANALYTICS

The Intersection of Genomics Research and the IDE Regulation

COPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES

Roche, Roche Molecular Diagnostics and more

Application of Deep Learning to Drug Discovery

MRC Biostatistics Unit

Genomic Research: Issues to Consider. IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC

Speed your time to market with FDA s expedited programs

SMEs in IMI2 Calls for Proposals

Controversy In Pharmacogenomics

A unique Collaborative Model for the Discovery of New Therapeutic Approaches

Planning for Phase III: Partnering NIH SBIR Conference 2017

Analytics in Healthcare. Preparing for advance healthcare analytics

Malaria Research Capability Strengthening in Africa

Updating International Ethics Guidelines for Stem Cell Research

Health Systems Engineering Call to action

European Medicines Agency Perspective

Real World Data Pilotprosjekt mellom LMI og Kreftregisteret; hvilken nytte kan industri og myndigheter ha av dette?

The Hybrid Model Combining OS and Proprietary Technologies

IRDiRC: International Rare Diseases Research Consortium

Future of the Project. BioMedBridges 3rd Annual General Meeting 18 February 2015, Munich Janet Thornton

Transcription:

Predictive Genomics for Prevention, Interception and Cure Health Datapalooza Emma Huang Population Analytics 27 April 2017 1

Looking to the future, our goal is to leverage the unprecedented advances in science to treat, intercept and prevent diseases in novel ways. Through a combination of internal expertise and external innovation, we hope to make a meaningful difference for patients all over the world. Bill Hait, Head of Janssen R&D 2

Accelerating learning across the health continuum Population-level data Clinical manifestation No clinical manifestation Onset of morbidity + HEALTHY: PREVENTION INCUBATION: INTERCEPTION DISEASE: CURE DTC genotyping Diagnostic Tests Clinical WGS PGx panels 3

Challenge 1: Integrating personalized data Global Initiatives linking human genetics & clinical phenotypes Kaiser Permanente > 200,000 + Amgen 300,000 UK Biobank 500,000 100,000 - Finnish Founder Population Geisinger + Regeneron 100,000 Estonia Precision Medicine Initiative Human Longevity + AstraZeneca 500,000 Veterans Affairs 1,000,000 Kadoorie Biobank ~500,000 China PMI 100,000,000 by 2030 > 1.4M 1,000,000 > 1M 100,000 4

End goal for predictive genomics: Using data collected from diverse instruments & sensors, we want to accurately map the probability for disease risk: P(D {G}, {E}, {L}, Gender, Age) taking into account family history, prior treatment, etc. P(D ) Disease Interception 50% 0 Age 5

Data needs depend on stage of health HEALTHY: PREVENTION INCUBATION: INTERCEPTION DISEASE: CURE Deeny and Steventon, BMJ Quality and Safety 2015 6

Challenge 2: Integrating stages of prediction Genomic prediction Predictive models to assess the risk of any disease, given genetic background PLATO: patient-level prediction Predictive models to assess the probability of a patient experiencing any outcome following initiation of any intervention, given personal medical history P(D ) Disease Interception 50% 0 Dynamic prediction of individual prognoses Predictive models to assess the probability of a patient experiencing outcomes given personal history (genetic, environmental, behavioral) Age 7

Population Analytics Biostatistics Longitudinal studies Statistical and population genomics Data integration Functional genomics What patients responded? Real world data Descriptive Why did they respond? Disease biology, PGx, etc. Diagnostic Given genetics, lifestyle, and environment, what is your risk for disease? Predictive If your risk is high, how should we intercept (and when)? And growing! Prescriptive How should we maintain wellness? Preemptive Hindsight Insight Foresight 8

Prevention Interception Cure Now Genomic prediction Molecular definitions of disease, biomarkers Subgroup characterization Shortterm Spatiotemporal data integration Dynamic prediction of individualized prognoses Prediction of response to interventions Longterm Feature extraction from continuous streaming Tracking of risk and need for intervention Prediction of disease progression and best intervention 9

Challenge 3: Translation to patients Retrospective study of phase III clinical trial Goal: identify genetic predictors of response to anti-tnf drug golimumab Data: clinical phenotypes and WGS for 436 RA patients Courtesy of Kris Standish 10

CURRENT BASELINE to FUTURE BASELINE Omics, SNPs for 1000s of people Validation, infrastructure and analytics to demonstrate value of data generation WGS, continuous sensing, linked with EHR for millions of people Widespread data generation adoption Understanding of how to add value with analytics; of what needs to be measured; of disease Widespread data analytics adoption Quantification of self Devices become unobtrusive; behavioral shift; evidence of value for health Effortlessly, and can be interpreted meaningfully Basis for regulation and payment is outcomes Definition of value; real-world evidence collection and analytics to quantify value Basis for regulation and payment is value Big data infrastructure for business Vendors with proven success in healthcare; collaborations between technology and healthcare industries Big data infrastructure for healthcare 11 11

Thanks! Xkcd.com